Grown hearts are outliving the models that predicted their failure

The first large cohort of grown-heart recipients has now lived ten years with hardware nobody had watched for ten years before. The follow-up released this week at the Earthside Public Health Commons carries a finding that is, in its own quiet way, a little insulting to the people who built the thing: the tissue is aging slower than its own engineers feared.

Of the first four thousand recipients tracked across Earthside and Lunar centers, more than ninety percent need no second organ. The original fabrication guidance assumed a replacement horizon, a soft expiry politely called a "maintenance interval," somewhere in the second decade. The data says the vasculature and conduction tissue are beating that number. In fairness to the modelers, these are people who remember waitlists. They were never going to promise you more than they had to.

"We planned for decline that has not arrived on schedule," said Dr. Imelda Cho, who directs the follow-up program. "That is a wonderful problem. It is also an expensive one to be wrong about in either direction."

The wrongness cuts two ways, which is usually how it works. Fabrication capacity, the grow-tanks, the technicians, the lift-constrained supply of certain substrates, was provisioned against the assumption that a meaningful fraction of recipients would come back. If the hearts last, that reserved capacity sits idle while other programs, grown-lung among them, run wards without beds. Recalibrate the schedule downward and you free that capacity for people still waiting on a first organ. Simple enough on paper.

That is where the room stopped nodding.

Recalibrating sounds like arithmetic. In practice it means telling the next cohort that the thing keeping them alive now gets checked less often, because the last four thousand did fine. The chart tells a different story about individual variance than it does about the population. Ninety percent is a reassuring number right up until you are standing in the other ten.

"Averages don't have chest pain," said Dr. Rafael Osei, a cardiologist who argued against moving the interval. "The cohort can outperform the model and still contain people whose tissue fails early. A surveillance schedule is how you find them before they find the floor."

The fabrication side wants the capacity regardless. The Lunar Districts, whose lung program has been rationing beds openly, have asked the Commons in writing whether freed heart-tank time could be reallocated across organ lines. The Accord's health annex does not obviously permit this. It does not obviously forbid it either, which is its own kind of diagnosis.

Cho's team declined to publish a revised interval along with the data, and that refusal is itself the news. They released the curves and no recommendation, a choice Cho defended as letting the numbers get a little older before anyone lets them become policy. It is a very doctorly instinct: don't treat the test result, treat the patient, and the patient here is an entire allocation system that has gotten used to scarcity and isn't sure what to do with ten good years.

The next cohort report is due at the following transfer window's data exchange with the Lunar centers. Until then the schedule stands. Every grown heart in the first four thousand remains on the books for its original check, whether or not it still needs one, which is either prudence or inertia wearing prudence's coat. The chart isn't telling us which yet.